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EDITORIAL
Patient Participation in Thoracic Cancer Clinical Trials
Jean-Louis Pujol, MD,*† Mohammad Chakra, MD,† and Bernard Milleron, MD*‡
Two recent articles published in the Journal of Thoracic Oncology1,2 are of particularimportance. It is noteworthy that clinical research is urgently needed in almost all
clinical settings of lung cancer from the early stage to metastatic disease. There is a
paradox that lung cancer, the leading cause of cancer mortality in both men and women
in the developed countries remains the “poor relative” of the clinical cancer research
programs with less than 5% of patients enrolling in trials. With a worldwide prognosis
remaining almost unchanged during the last decade, it is glaringly obvious that the low
participation of patients with thoracic cancer in clinical trials is a major challenge for
advancing the field.
At the same time, we are facing a dramatic increase in the lung cancer epidemic in
many developed countries, particularly in European women,3 and the situation is worse in
many Asian and African countries inasmuch as lung cancer incidence greatly reflects
smoking behaviors.4 Increasing patient participation in thoracic cancer clinical trials is
therefore mandatory and the two aforementioned articles help our discussion of this topic:
There are four different questions about patients’ participation in clinical trials:
1. Is low patient participation in clinical trials a myth or reality?
2. Does insufficient patient participation have consequences in clinical research
progress?
3. What are the mechanisms of resistance that limit patient participation?
4. Are we able to improve this participation?
THE LOW PARTICIPATION OF PATIENTS IN THORACIC
CANCER TRIALS
Although lung cancer is a worldwide problem the proportion of patients included in
clinical trials remains low, as clearly established by Sateren et al. in a recent publication.5
The proportion of male patients afflicted by lung cancer represents 14% of total U.S.
cancer burden but only 9% of cancer clinical trial patients. The respective proportions for
women are 12.6% and 4.6%. However, the main parameter influencing patient accrual
were age, ethnicity, insurance status, and presence of oncology specialist and hospital near
the place of residence.5 Similar observations are been performed in analyzing disparities
of participation in National Cancer Institute clinical trial cooperative groups pointing out
the low participation in lung cancer clinical trials. In addition, racial and ethnic minorities,
women, and the elderly were less likely to enroll in cooperative group clinical trial.6 One
can also observe the dramatic difference existing between screening programs for breast
cancer, now adopted in many countries and undoubtedly having partially been responsible
for breast cancer mortality reduction,7 and the lung cancer screening by low-dose computed-
tomography scan, remaining at an experimental approach.8 To date, for high-risk popula-
tions, no screening modality has been shown to reduce lung cancer mortality even if it
could be expected that early-stage disease can be successfully treated.
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CONSEQUENCES OF INSUFFICIENT
PATIENT PARTICIPATION
The direct consequences of the insufficient patient par-
ticipation in thoracic cancer clinical trials and particularly in
lung cancer research may be the overall slow rhythm of
scientific advance. The emergence of new concepts, valida-
tion of new approaches such as combined treatment modali-
ties or adjuvant chemotherapy, new cytotoxic drugs, new
targeted-agents clearly offer the patient new possibilities of
longer survival. However, these results are only observed in
the setting of clinical trials and encounter difficulties of
translation to the global lung cancer patient population.
Notwithstanding, recent major advances in thoracic
cancer treatment have been achieved. The improvement of
the condition of the general population is slow and, in our
opinion, the low participation of lung cancer patients in
clinical trials is not only a quantitative concern, but also, a
qualitative one. Several studies of sociodemographic features
characterizing cancer patient accrual in clinical trails have
highlighted that some important subsets of patients are un-
derrepresented in research programs, particularly, patients
older than 75 years, persons with poor socio-economic con-
ditions, people living without insurance, and ethnic minori-
ties. The case of the former group of patients, i.e., patients
older than 75 years, has been extensively discussed.9 Most of
the therapeutic controlled trials performed during the past 15
years have systematically excluded patients older than 70 to
75 years. Therefore, extrapolations of therapeutic advances
observed in younger patients with good clinical status are
speculative. Development of specific research in the elderly is
urged.10 Consequently, impact of new strategies in the gen-
eral population cannot spread far from the original population
of young patients treated in clinical trials.
Similarly, patients afflicted by common comorbidities
such as coronary artery, renal insufficiencies, or severe chronic
obstructive pulmonary disease (COPD), are frequently excluded
from clinical trials. However, when considering the Charlson
comorbidity Index (CCI) in a general (unselected) population of
lung cancer, one can easily observed that most of the patients are
afflicted by a CCI 3 or more.11
The under representation of ethnic minorities is also an
important concern, because, in several countries such as in
United States of America12 and in New-Zealand,13 these
patients are afflicted by a poorer prognosis when compared
with non-Hispanic Caucasian sub populations. One can hy-
pothesize that the improvement of survival, such as it is
regularly observed in clinical trials, cannot be directly trans-
posed because the population accrued in these studies did not
reflect the heterogeneity of the lung cancer population socio-
demographic characteristics.
MECHANISMS OF RESISTANCE
What are the mechanisms limiting clinical research
efforts in thoracic cancers? There is undoubtedly more than
one reason for explaining such a complex situation.
One of the limitations that were observed in the past
was the lack of widely available clinical trials. This is not the
case any longer. On a quantitative and qualitative point of
view, there was a clear improvement in methodological
qualities, statistical power, and scientific interest of recent
clinical trials. Excellent clinical trials have been conducted
during the past decade by cooperative groups and pharmaceuti-
cal companies; now there are many opportunities for patients to
participate in clinical trials. However one might consider that
this effort is mainly concentrated in non-small cell lung
cancer and that, conversely, programs for small cell lung
cancer or rare diseases such as thymoma are not in sufficient
number to advance our knowledge of these diseases.
Another limitation could be the lack of information
addressed to the general pubic regarding opportunity of
research programs. However, researching the medical litera-
ture for scientific programs in lung cancer has been greatly
improved by the internet, explaining to the patient most of
important research programs and offering the patients fair and
accurate resources such as via the Patient Information Web-
site of the American Society of Clinical Oncology (http://
www.plwc.org/).
The publication by Dr Quinn et al. helps us to under-
stand where psychologic resistances from patients might limit
participation in clinical trials.1 This study demonstrated that
the disease by itself, i.e., lung cancer, has a particularly
negative outlook in the general population regarding its low
curability. In addition, the public considers that lung cancer is
mainly a self-inflicted disease. These features might induce
strong feelings for the patient suffering from thoracic cancer,
feelings of guilty hopelessness. Both psychologic parameters
are limiting the willingness to participate in clinical trials.
Therefore, patients with lung cancer may be more inclined to
prefer standard treatments because these later are expected to
induce less time wasted for treatment when compared with
clinical trials. The merit of this study is to highlight this
phenomenon and to propose a simple letter sent to the patient to
improve understanding that it is his/her own interest to consider
participation in a clinical trial,1 a clinical benefit that was
observed by other authors for patients with breast cancer.14
HOW CAN PATIENT PARTICIPATION IN
CLINICAL TRIALS BE IMPROVED?
In our opinion, there are two different ways to reach
this goal. The first would be to improve the accessibility of
clinical trials for the patients, i.e., improve the information
delivered to patients regarding research options for their disease;
the second would be to change our method of designing clinical
trials to more widely accrue the reality of lung cancer patient
demography in the current research programs.
Improving the accessibility of clinical trials has been
attempted in several ways. Educational booklets about the
clinical trial have been proposed.15 The aforementioned letter
as proposed by Dr Quinn et al.1 is a very interesting attempt
to present the patient, before their first medical appointment,
what is a clinical research option and why this option may be
the best therapeutic option. In their publication, the authors
suggested that the participation in clinical trials in thoracic
oncology programs have trended toward improvement after
this letter was introduced into their routine practice. This
might be taken as a simple clue, as stated by Dr Quinn,
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insofar as there was no randomization, all patients having
received the letter. Some bias could have participated in the
improvement in patient participation such as global effort of
the institution to improve the accrual. However, because this
letter is simple clear and tactful, it is a very good way to
improve the patient—doctor relationship whether or not the
patient finally decides to participate in a clinical trial.
A more structured intervention is presented in the
second study2 published by Dr DU et al. in the current issue
of the journal. Patients were randomly assigned to watch an
18-minute educational video before their first meeting with an
oncologist or to directly meet the physician. This study aims
at determining whether this educational medium increases
patient willingness to participate in clinical trials and finally
increases clinical trial accrual.
The main conclusion is that there was a significant effect
of intervention (video viewing) versus no intervention so that
patients’ self-assessed likelihood to enroll score has been signif-
icantly increased in the “video” group. The analysis detected that
the educational intervention was a predictive factor of patient’s
willingness to participate in clinical trials.
As clearly discussed by the authors, this likelihood to
enroll score did not directly translate into a significant in-
crease in patient participation. The reason for this discrep-
ancy might lay in the fact that patient willingness is not the
only factor allowing participation in a research programs. Other
conditions have to be met. One of them is that disease charac-
teristics and patient eligibility criteria for a specific study.
Patient participation in clinical trial could be improved
if two conditions were met. First, improving accessibility and
quality of information directed to global public and the
patient to reduce fears of being involved in an experimental
treatment and second, improving clinical design to broaden
eligibility criteria to offer elderly patients or patients with
comorbidities, tailored clinical trials.
In conclusion, both articles by Dr Quinn and by Dr DU
help us to consider the patient neither as a guinea pig nor as a
martyr for a scientific cause, but as an individual and a partner
in the improvement of lung cancer treatment and our under-
standing of the disease biology. We thank all patients who have
consented to confidently participate in research trials.
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